Top Story

Top GOP Senators Question CMS Head On Recouping Lost SBM Funds

Republican Sens. Orrin Hatch of Utah, Chuck Grassley of Iowa and John Barrasso of Wyoming on Monday (Aug. 3) showed their displeasure over mismanaged state exchange funds in a letter to acting CMS Administrator Andy Slavitt, saying that millions of dollars in taxpayer money should be recovered by the federal government.

Latest News

Sen. Robert Casey (D-PA) introduced his own version of legislation to make the FDA pediatric priority review program permanent, as well as modify the definition of “rare pediatric disease” to include any form of sickle cell disease and any pediatric cancers.

As the Senate health committee continues work on its Innovation for Healthier Americans initiative, sources say the upper chamber has not shown much interest in pursuing a mandatory funding stream for the National Institute of Health as was included in the recently passed House 21st Century Cures bill.

House Energy & Commerce Committee leaders are questioning FDA's policy of not routinely conducting good manufacturing practices inspections at facilities that use drugs solely for research purposes, as lawmakers step up their probe of the recent closure of a section of NIH's Clinical Center Pharmacy Department that manages investigational drugs.

FDA alerted users of Hospira's Symbiq Infusion System that the product has cybersecurity vulnerabilities, and encouraged health care facilities to transition to alternative infusion systems Friday (July 31).

CMS on Friday (July 31) issued final pay rules for services in five areas: hospitals, long-term care hospitals, hospice, inpatient rehabilitation facilities and inpatient psychiatric facilities.

Providers, vendors and other health IT stakeholders are asking CMS to quickly finalize its proposed rule adding additional flexibility to the troubled meaningful use program in 2015 through 2017, as providers are quickly running out of time to make the necessary changes the rule would require.

CMS actuaries projected Medicare Part D spending increased 17.3 percent last year, which would be the biggest growth rate in the history of the drug benefit, and they projected that Medicaid spending on drugs increased 23.3 percent.

A recently released white paper raised concerns over the pharmaceutical industry's influence in continuing medical education courses, specifically the use of disease-marketing as an alleged “back-door” approach to promoting products not yet approved by FDA.